DexCom, Inc. Forecast, price target & analysts
DexCom, Inc. Target price 2025 - Analyst rating & recommendation
DexCom, Inc. Classifications & Recommendation:
DexCom, Inc. Price Target
| Target Price | $102.51 |
| Price | $83.89 |
| Potential | 22.20% |
| Number of Estimates | 29 |
| 29 Analysts have issued a price target DexCom, Inc. 2026 . The average DexCom, Inc. target price is $102.51. This is 22.20% higher than the current stock price. The highest price target is $120.75 43.94% , the lowest is $85.85 2.34% . | |
| A rating was issued by 34 analysts: 29 Analysts recommend DexCom, Inc. to buy, 5 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the DexCom, Inc. stock has an average upside potential 2026 of 22.20% . Most analysts recommend the DexCom, Inc. stock at Purchase. |
Sales and Margin forecast 2025, 2026 to 2030
31 Analysts have issued a sales forecast DexCom, Inc. 2025 . The average DexCom, Inc. sales estimate is $4.7b . This is 13.50% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $4.9b 19.07% , the lowest is $4.5b 7.93% .
This results in the following potential growth metrics:
Revenue Estimates
| 2024 | $4.0b | 11.34% |
|---|---|---|
| 2025 | $4.7b | 16.74% |
| 2026 | $5.4b | 15.42% |
| 2027 | $6.2b | 14.67% |
| 2028 | $7.2b | 15.34% |
| 2029 | $7.9b | 10.00% |
| 2030 | $8.5b | 7.30% |
24 Analysts have issued an DexCom, Inc. EBITDA forecast 2025. The average DexCom, Inc. EBITDA estimate is $1.4b . This is 58.66% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $1.5b 72.65% , the lowest is $1.2b 34.53% .
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Estimates
| 2024 | $871m | 39.97% |
|---|---|---|
| 2025 | $1.4b | 56.22% |
| 2026 | $1.7b | 23.00% |
| 2027 | $2.0b | 21.80% |
| 2028 | $2.6b | 29.28% |
| 2029 | $3.0b | 15.36% |
| 2030 | $3.2b | 3.68% |
EBITDA Margin
| 2024 | 21.60% | 25.72% |
|---|---|---|
| 2025 | 28.91% | 33.83% |
| 2026 | 30.81% | 6.57% |
| 2027 | 32.72% | 6.20% |
| 2028 | 36.68% | 12.10% |
| 2029 | 38.46% | 4.85% |
| 2030 | 37.17% | 3.35% |
30 DexCom, Inc. Analysts have issued a net profit forecast 2025. The average DexCom, Inc. net profit estimate is $812m . This is 51.70% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $881m 64.62% , the lowest is $749m 40.00% .
This results in the following potential growth metrics and future Net Margins:
Net Profit Estimates
| 2024 | $576m | 6.41% |
|---|---|---|
| 2025 | $812m | 40.91% |
| 2026 | $1.0b | 24.96% |
| 2027 | $1.3b | 23.25% |
| 2028 | $1.5b | 22.66% |
| 2029 | $1.8b | 16.62% |
| 2030 | $1.9b | 5.42% |
Net Margin
| 2024 | 14.29% | 4.43% |
|---|---|---|
| 2025 | 17.25% | 20.74% |
| 2026 | 18.67% | 8.23% |
| 2027 | 20.07% | 7.50% |
| 2028 | 21.34% | 6.33% |
| 2029 | 22.63% | 6.04% |
| 2030 | 22.23% | 1.77% |
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2030
30 Analysts have issued a DexCom, Inc. forecast for earnings per share. The average DexCom, Inc. EPS is $2.07 . This is 59.23% higher than earnings per share in the financial year 2024. The highest EPS forecast is $2.25 73.08% , the lowest is $1.91 46.92% .
This results in the following potential growth metrics and future valuations:
Earnings Per Share
| 2024 | $1.40 | 10.24% |
|---|---|---|
| 2025 | $2.07 | 47.86% |
| 2026 | $2.59 | 25.12% |
| 2027 | $3.19 | 23.17% |
| 2028 | $3.91 | 22.57% |
| 2029 | $4.56 | 16.62% |
| 2030 | $4.81 | 5.48% |
P/E ratio
| Current | 64.53 | 10.04% |
|---|---|---|
| 2025 | 40.51 | 37.22% |
| 2026 | 32.42 | 19.97% |
| 2027 | 26.31 | 18.85% |
| 2028 | 21.45 | 18.47% |
| 2029 | 18.39 | 14.27% |
| 2030 | 17.44 | 5.17% |
Based on analysts' sales estimates for 2025, the DexCom, Inc. stock is valued at an EV/Sales of 6.94 and an P/S ratio of 6.99 .
This results in the following potential growth metrics and future valuations:
EV/Sales
| Current | 7.88 | 31.24% |
|---|---|---|
| 2025 | 6.94 | 11.88% |
| 2026 | 6.02 | 13.36% |
| 2027 | 5.25 | 12.79% |
| 2028 | 4.55 | 13.30% |
| 2029 | 4.14 | 9.09% |
| 2030 | 3.85 | 6.80% |
P/S ratio
| Current | 7.93 | 31.73% |
|---|---|---|
| 2025 | 6.99 | 11.90% |
| 2026 | 6.05 | 13.36% |
| 2027 | 5.28 | 12.79% |
| 2028 | 4.58 | 13.30% |
| 2029 | 4.16 | 9.10% |
| 2030 | 3.88 | 6.80% |
Current DexCom, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Mizuho |
Outperform
➜
Outperform
|
Unchanged | Jul 16 2025 |
| Morgan Stanley |
Equal-Weight
➜
Equal-Weight
|
Unchanged | Jul 15 2025 |
| Truist Securities |
➜
Buy
|
Initiated | Jun 16 2025 |
| Goldman Sachs |
➜
Buy
|
Initiated | May 30 2025 |
| Citigroup |
Buy
➜
Buy
|
Unchanged | May 22 2025 |
| Barclays |
Equal-Weight
➜
Equal-Weight
|
Unchanged | May 05 2025 |
| Canaccord Genuity |
Buy
➜
Buy
|
Unchanged | May 02 2025 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
Mizuho:
Outperform
➜
Outperform
|
Jul 16 2025 |
|
Unchanged
Morgan Stanley:
Equal-Weight
➜
Equal-Weight
|
Jul 15 2025 |
|
Initiated
Truist Securities:
➜
Buy
|
Jun 16 2025 |
|
Initiated
Goldman Sachs:
➜
Buy
|
May 30 2025 |
|
Unchanged
Citigroup:
Buy
➜
Buy
|
May 22 2025 |
|
Unchanged
Barclays:
Equal-Weight
➜
Equal-Weight
|
May 05 2025 |
|
Unchanged
Canaccord Genuity:
Buy
➜
Buy
|
May 02 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
